The Application Notebook
Dionex Application note
Endothall is a widely used herbicide for both terrestrial and aquatic weeds. Exposure to endothall in excess of the maximum contamination level (MCL) can cause illness. Endothall is regulated by the US Environmental Protection Agency (EPA) at 100 ppb in drinking water, and by the California EPA at 0.58 mg/L, or 580 ppb, as the Public Health Goal. Current analytical methods described in EPA method 548.1 for the quantification of endothall in water samples involve time-consuming sample preparation and derivatization followed by a 20-min analysis by GC–MS or GC–FID.
This study describes the direct analysis of trace levels of endothall in water samples by ion chromatography–mass spectrometry (IC–MS). Water samples were directly injected for analysis and chromatographic separation was reduced to 10 min. The MSQ Plus mass spectrometer was operated in selected ion monitoring (SIM) mode, allowing minimum sample cleanup and ensuring sensitive (low ppb) and selective quantification. Isotope labelled glutaric acid (Glutarate–d6) was used as the internal standard to ensure quantification accuracy.
As seen in Figure 1, endothall was retained and separated from seven commonly seen anions within 10 min, and was detected with great sensitivity and selectivity using SIM acquisition. This method features direct analysis without sample pretreatment and significantly reduces run time relative to GC methods, thus improving throughput. Sufficient sensitivity was achieved in this study to allow the routine quantification of endothall below the lowest regulated level (100 ppb by US EPA standards).
Figure 1: ICâMS of 20 ppb endothall spiked in a seven anions matrix: 0.2â1.5 ppm.
IonPac is a registered trademark of Dionex Corporation. MSQ Plus is a trademark of Thermo Fisher Scientific.
Dionex Corporation
1228 Titan Way, PO Box 3603, Sunnyvale, California 94088, USA
tel: +1 408 737 0700 fax: +1 408 730 9403
Website: www.dionex.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.